Shum

INVO Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 15, 2023
IVC, Loss, Clinic, Bank statement, Shum, Calendar, GAAP, IVF, Interest, EBITDA, Acquisition, Patient, Investment, Fertility, Pharmaceutical industry, Video game, Cryptocurrency, Bank

SARASOTA, Fla., May 15, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the quarter ended March 31, 2023 and provided a business update.

Key Points: 
  • SARASOTA, Fla., May 15, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the quarter ended March 31, 2023 and provided a business update.
  • All reported clinic revenue is derived from the Company's INVO Center in Atlanta, Georgia, which is consolidated in the Company's financial statements.
  • Clinic revenue from the Company's consolidated INVO Center was $297,381 during the first quarter of 2023, an increase of 114% compared to $105,848 for the three months ended March 31, 2022.
  • INVO has scheduled a conference call for Monday, May 15, 2023, at 4:30 pm ET (1:30 pm PT) to review these results and recent events.

INVO Provides Preliminary Update on FY2022 Financial Results

Retrieved on: 
Thursday, March 30, 2023
IVC, File, Bank statement, Shum, Calendar, IVF, Acquisition, Annual report, Growth, Ferring, Security (finance), Video game, Pharmaceutical industry, Cryptocurrency

SARASOTA, Fla., March 30, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced preliminary financial results for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • SARASOTA, Fla., March 30, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced preliminary financial results for the fourth quarter and year ended December 31, 2022.
  • Gross operating expenses, inclusive of non-cash charges, are expected to be comparable to the third quarter of 2022.
  • "Consummation of our planned Wisconsin Fertility Institute acquisition is expected to provide INVO with the ability to accelerate our business plan and significantly improve our financial profile.
  • We look forward to hosting our regular investor call within the next two weeks and to provide additional details on our financial results, the acquisition and INVO's prospects and plans."

Harry Shum Appointed Chairman of the Board of Silicon Valley Startup News Break

Retrieved on: 
Wednesday, May 27, 2020
Businesspeople, Economy of the United States, Verizon Media, Yahoo!, Harry Shum, Yang, Companies, Shum

1 news app in the U.S. market, today announced the appointment of Harry Shum to Chairman of the Board.

Key Points: 
  • 1 news app in the U.S. market, today announced the appointment of Harry Shum to Chairman of the Board.
  • We are thrilled Harry is joining News Breaks board as Chairman, said Jeff Zheng, Founder and CEO at News Break, an ex-Yahoo executive and serial entrepreneur.
  • Dr. Harry Shum is a world-renowned scientist and educator in computer science and artificial intelligence.
  • Founded in Silicon Valley in 2015, with Yahoo co-founder Jerry Yang as Chief Advisor, News Break is the worlds first Intelligent Local News Platform.

Asensys Announces Former Executive Vice President of Artificial Intelligence & Research at Microsoft Dr. Harry Shum as an Angel Investor

Retrieved on: 
Thursday, March 5, 2020
Harry Shum, Shum

SEATTLE, March 5, 2020 /PRNewswire-PRWeb/ -- Asensys , a next-generation, high-performance system that brings throughput and capacity to a new, scalable level, is pleased to announce former Executive Vice President of Artificial Intelligence & Research at Microsoft Dr. Harry Shum as an angel investor.

Key Points: 
  • SEATTLE, March 5, 2020 /PRNewswire-PRWeb/ -- Asensys , a next-generation, high-performance system that brings throughput and capacity to a new, scalable level, is pleased to announce former Executive Vice President of Artificial Intelligence & Research at Microsoft Dr. Harry Shum as an angel investor.
  • Dr. Shum is a famous AI researcher, who is an IEEE Fellow and an ACM Fellow for his contributions to computer vision and computer graphics.
  • Dr. Shum's expertise in AI will provide Asensys with an advantage in building a system that works for an increasingly AI-powered economy.
  • "I'm honored to announce Harry Shum, as an angel investor in Asensys," said Asensys Founder Dr. Wang.